Mid-Atlantic Region III Core Center for Federally Funded HTCs

A national network of more than 140 Hemophilia Treatment Centers (HTCs) is supported and funded by the Maternal and Child Health Bureau (MCHB) of the Health Resources and Services Administration (HRSA) and the Centers for Disease Control and Prevention (CDC). HTCs are specialized health care centers staffed by a team of doctors, nurses, social workers, physical therapists and other health professionals with expertise in the treatment of bleeding disorders.

Mid-Atlantic Region III Core Center: Regional Statistics

The 16 Hemophilia Treatment Centers in Mid-Atlantic Region III report statistics regarding their patient population to the Core Center annually. This information is used for reporting to our federal grant agency, the Maternal and Child Health Bureau, and is also used by the Core Center for monitoring, budget apportionments and program planning.

Active patients by age, race and gender

In 2022, HTCs in the Mid-Atlantic Region reported 4,272 total patients with bleeding disorders.

  • 37% female; 63% male
  • 77% Caucasian
  • 14% African American
  • 7% Hispanic

Active patients by diagnosis

Patients with bleeding disorders:

  • Hemophilia A or B: 2,121 patients (50%)
  • Von Willebrand disease: 1,371 patients (32%)

Patients with Thrombosis:

  • 936 patients were reported in our region from 11 of our HTCs; 56% of these patients are female.

Patients with other factor deficiencies:

  • 316 patients with a deficiency in factor I, II, V, VII, X, XI or XIII. These patients represent 7% of the patients in the region.

Evaluations

  • 3,193 comprehensive evaluations were conducted at HTCs in 2022.

Home therapy

  • 1,161 patients with hemophilia (27%) are on home therapy.

Primary care physicians (PCPs)

  • 3,971 patients in Mid-Atlantic Region had an identified PCP.